

Outcomes in patients with ischemic stroke and newly diagnosed atrial fibrillation after stroke

Yu-Kang Chang, PhD; Chih-Cheng Hsu, MD, PhD; Chi-Ting Huang, MD; Chi-Hsun Lien, MD; \*Hung-Yi Hsu, MD, PhD.

**\*Correspondence to:** Dr. Hung-Yi Hsu, Department of Neurology, Tungs' Taichung Metro Harbor Hospital, No. 699, Sec. 8, Taiwan Boulevard, Wuqi District, Taichung City 43503, Taiwan, R.O.C.

Fax: +886-4-26582193. Tel: +886-9-10597960. E-mail: [hungyihsu@gmail.com](mailto:hungyihsu@gmail.com)

**Category of article: Original contributions**

**Running title:** High recurrent stroke risk in newly diagnosed AF.

**Key words:** Atrial fibrillation, Ischemic stroke, Mortality, Prognosis.

The paper includes 5 tables and 1 supplemental table.

## ABSTRACT

**BACKGROUND:** The clinical characteristics and long-term outcomes of patients with ischemic stroke (IS) and newly diagnosed atrial fibrillation after stroke (NAF) have not been clearly established. Previous studies evaluating patients with NAF were limited by the low prescription rates of anticoagulants and short follow-up periods.

**METHODS:** Consecutive patients hospitalized for IS between 2014 and 2017 were identified from a National Health Insurance Research Database. The included patients were categorized into three groups: (1) known diagnosis of AF (KAF) before the index stroke, (2) NAF, and (3) without AF (non-AF). Univariable and multivariable Cox regression analyses were performed to estimate the hazard ratio (HR) for independent variables and recurrent IS, hemorrhagic stroke, or death.

**RESULTS:** We identified 158,909 patients with IS of whom 16,699 (10.5%) had KAF and 7,826 (4.9%) had NAF. The patients with NAF were younger, more often male, and had lower CHA<sub>2</sub>DS<sub>2</sub>-VASc scores ( $3.8 \pm 1.9$  versus  $4.9 \pm 1.8$ ,  $p < 0.001$ ) than the patients with KAF. Anticoagulant treatment significantly reduced the risks of all outcomes. Compared with NAF, KAF was associated with lower risks of recurrent IS [hazard ratio (HR): 0.91, 95% confidence interval (CI): 0.86–0.97,  $p < 0.01$ ] and hemorrhagic stroke (HR: 0.88, 95% CI: 0.79–0.99,  $p < 0.01$ ) and a higher risk of all-cause mortality (HR: 1.11, 95% CI: 1.07–1.16,  $p < 0.001$ ). The risks of all three outcomes were significantly higher for both NAF and KAF than for non-AF.

**CONCLUSIONS:** The risks of recurrent IS and hemorrhagic stroke were higher and of all-cause mortality was lower for patients with NAF than with KAF. Anticoagulant therapy significantly reduced the risks of recurrent IS, hemorrhagic stroke, and all-cause mortality.

## INTRODUCTION

Atrial fibrillation (AF) related ischemic strokes (IS) are more often fatal or disabling than IS from other causes.<sup>1</sup> On the other hand, IS is a strong independent predictor of future stroke and death in patients with AF.<sup>2-4</sup> Patients with AF who ever experienced IS or transient ischemic attack (TIA) are at a higher risk of future adverse events. However, the long-term outcomes of the subgroup of AF patients with IS have not been well addressed in clinical studies.

Patients with IS may have had previously known AF (KAF) or have newly diagnosed AF after experiencing a stroke (NAF). Substantial differences in comorbidities and outcomes might exist between KAF and NAF. Patients with NAF might have a lower risk of recurrent stroke and less cardiovascular comorbidity, including coronary heart disease, myocardial infarction, and heart failure than those of patients with KAF.<sup>5</sup> Other studies have reported that NAF had outcomes and comorbidities similar to those of KAF<sup>6</sup> or had an even higher risk of death than that of KAF.<sup>7</sup> These discrepancies among different studies may be because of differences in populations, nomenclature of AF, methods of data collection, and diagnostic workups for AF detection. Moreover, previous studies were limited by a low rate of anticoagulation use and only a 1-year follow-up.<sup>5,6,8</sup> Only a few studies have reported the long-term outcomes of patients with IS and AF.<sup>7</sup> The differences in long-term outcomes between KAF and NAF need confirmation by more studies.

Current guidelines have suggested that anticoagulants, including vitamin-K antagonists and direct-acting oral anticoagulants (DOACs), effectively reduced the risks of IS and systemic embolization in patients with AF.<sup>4,9,10</sup> However, the prescription rates of anticoagulants in previous studies of patients with NAF were relatively low.<sup>5,6,8</sup> The benefits of anticoagulant treatment in NAF and the long-term prognosis need further investigation.

The aims of this study were to evaluate the clinical characteristics of NAF in patients with IS in a large population-based cohort; the differences in comorbidities and outcomes among the patients with KAF, NAF, and without AF; and the effects of anticoagulant treatment in patients with IS with either KAF or NAF.

## **METHODS**

### **Data resources**

This study used data from the National Health Insurance (NHI) program, which was established in 1995 to offer comprehensive coverage for hospitalization and outpatient services and prescription medications to >99% of the residents of Taiwan. The NHI served as the primary data source for this study. This was a retrospective study of data for patients with stroke retrieved from the National Health Insurance Research Database (NHIRD) of the NHI program. Since the data does not contain personally identifying information, the Institutional Review Board of this hospital determined after a thorough review that informed consent was unnecessary for this study.

### **Study population**

We identified adult patients who were hospitalized for IS between 2014 and 2017 on the basis of the International Classification of Diseases (ICD), 9<sup>th</sup> and 10<sup>th</sup> editions, Clinical Modification (ICD-9-CM and ICD-10-CM) codes, including ICD-9-CM codes 433.x and 434.x as well as ICD-10-CM codes I63.x, I65.x, and I66.x as the principal discharge diagnosis. The AF diagnosis was based on the ICD-9-CM code 427.31 and ICD-10-CM codes I48.0, I48.1, I48.2, and I48.91. According to these patients' histories of AF diagnosis, we categorized them into three groups: (1) KAF (patients with a known diagnosis of AF before the index stroke), (2) NAF (patients with no previous diagnosis of AF but AF detected during their hospital stay for the index stroke), and (3) non-AF (patients without AF). The first hospitalization for the IS during this period was designated as the index hospitalization. The admission date was defined as the index date.

### **Independent variables**

We collected demographic variables, including sex, age, and comorbidities, from the NHI program datasets. These comorbidities included hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, heart failure, peripheral vascular disease, chronic kidney disease, chronic obstructive pulmonary disease, and prior stroke/TIA. All of the main comorbidities were based on diagnosis codes (Supplemental Table 1) from at least one prior hospitalization or two prior outpatient visits during the 1-year period before the index hospitalization. The diagnostic accuracies of important comorbidities in NHIRD, such as hypertension, diabetes mellitus, heart failure, myocardial infarction, hyperlipidemia, and chronic obstructive pulmonary disease, have been previously validated.<sup>11,12</sup>

A modified Charlson Comorbidity Index score was used to summarize comorbidity.<sup>13</sup>

Due to the unavailability of clinical stroke scales in the claims data, we employed the stroke severity index (SSI) that is a validated surrogate for assessing stroke severity.<sup>14</sup> The SSI proved particularly valuable for adjusting the case mix in mortality models involving patients with IS in instances in which a traditional clinical stroke scale was not accessible. The SSI comprises seven components that can be readily extracted from the index hospitalization claims. The SSI values have a strong correlation with National Institutes of Health Stroke Scale (NIHSS) scores<sup>14</sup> at admission and could be converted into estimated NIHSS scores.<sup>15</sup> Accordingly, the estimated NIHSS scores were categorized as mild (<8), moderate (8–15), or severe (>15) stroke, aligning with a previous study that used the NIHSS to prognosticate stroke outcomes. The CHADS<sub>2</sub><sup>16</sup> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores<sup>3</sup> were also calculated for all patients. Antithrombotic treatments of study subjects were divided into antiplatelet agents, warfarin, and DOACs groups on the basis of NHI drug codes and Anatomical Therapeutic Chemical codes.

### **Outcome variables**

We sought to evaluate outcomes encompassing recurrent IS, hemorrhagic stroke, or death. Mortality status was based on the cause of death data from NHI. Patient follow-up continued until any recurrence of IS, hemorrhagic stroke, death, or December 31, 2017, whichever came first.

### **Statistical analysis**

We presented continuous variables as means with standard deviations and presented categorical variables as counts with percentages. To compare baseline characteristics among the KAF, NAF, and non-AF groups, we used Chi-square tests for categorical variables and One-way analysis of variance for continuous variables. Univariable and multivariable Cox regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for each independent variable as well as the outcomes, including recurrent IS, hemorrhage stroke, and all-cause mortality. We ensured that all independent variables met the proportional hazards assumption by performing the Schoenfeld residuals test. All *p*-values were two-sided, and those <0.05 were accepted as indicating statistical significance. SAS 9.4 software (SAS Institute Inc., Cary, North Carolina, USA) was used to perform all statistical analyses.

## RESULTS

Overall, 158,909 patients with IS were included in this study. Among these patients, 16,699 (10.5%) had KAF and 7,826 (4.9%) had NAF. The demographic characteristics of the different groups are presented in Table 1. Compared with the NAF patients, the KAF patients were older, more likely to be female, and had higher CHA<sub>2</sub>DS<sub>2</sub>-VASc scores and incidences of comorbidities, excluding hyperlipidemia. Compared with the non-AF group, the NAF group was older, had more female patients, and exhibited more comorbidities except for peripheral arterial disease and chronic obstructive pulmonary disease. There were no significant differences in the SSI scores and estimated NIHSS between the KAF and NAF groups. However, the non-AF group had lower CHA<sub>2</sub>DS<sub>2</sub>-VASc scores, SSI values, and estimated NIHSS scores than those in both the KAF and NAF groups.

The prescription rate of DOACs was higher in the NAF group (48.8%) than in the KAF (36.6%,  $p < 0.001$ ). Significant differences were observed in all outcome measures (recurrent IS, hemorrhagic stroke, and all-cause mortality) among the three groups. The rates of recurrent IS and hemorrhagic stroke were highest in the NAF patients, whereas the all-cause mortality rate was highest in the KAF patients. The standardized mortality rates were 40.4, 28.6, and 18.4 (per 100 person-years) for the patients with KAF, NAF, and non-AF, respectively.

The results of univariable and multivariable Cox regression models for predicting recurrent IS, hemorrhagic stroke, and all-cause mortality are presented in Tables 2, 3, and 4, respectively. Risk factors for recurrent IS and all-cause mortality included male sex, age from 65–74 years, hypertension, diabetes mellitus, heart failure, prior stroke or TIA, severity of index stroke, KAF, and NAF (Tables 2 and 4). Male sex, age >75 years, severity of index stroke, KAF, and NAF increased the risk of recurrent hemorrhagic stroke. Coronary artery disease, prior stroke or TIA, and anticoagulant treatment reduced the risk of recurrent hemorrhagic stroke (Table 3). Anticoagulant treatment significantly reduced the risks of recurrent IS (HR: 0.35, 95% CI: 0.33–0.36,  $p < 0.001$ ), hemorrhagic stroke (HR: 0.42, 95% CI: 0.38–0.45,  $p < 0.001$ ), and all-cause mortality (HR: 0.51, 95% CI: 0.49–0.52,  $p < 0.001$ ). Comparisons of the three outcome measures among the patients with non-AF, NAF, and KAF after adjusting for age and risk factors are summarized in Table 5. Compared with NAF, the patients with KAF had lower risks of recurrent IS (HR: 0.91, 95% CI: 0.86–0.97,  $p < 0.01$ ) and hemorrhagic stroke (HR: 0.88, 95% CI: 0.79–0.99,  $p < 0.01$ ) and a higher risk of all-cause mortality (HR: 1.11, 95% CI: 1.07–1.16,  $p < 0.001$ ). Both NAF and KAF groups had significantly higher risks of all three outcomes than those of the

non-AF group.

## DISCUSSION

This study evaluated the clinical characteristics and outcomes of patients with IS and KAF, NAF, and non-AF in a real-world Chinese cohort. The large patient population and longer follow-up period provided valuable information that will contribute to a better understanding of the possible effects of AF in patients with IS and of the potential interventions for these patients. In our cohort, the incidence of severe stroke was twice as frequent in the patients with AF than in the patients without AF. Previous studies also showed that AF-associated strokes tended to be more severe and debilitating.<sup>4,17</sup> The stroke severity indices were not different between KAF and NAF. Compared with non-AF, both KAF and NAF were associated with increased risks of recurrent IS, future hemorrhagic stroke, and all-cause mortality even after adjusting for traditional risk factors.

The incidence of all-cause mortality was significantly higher in the KAF group than in the NAF group. An early study in the same region of Taiwan also found that the 1-year mortality rate was significantly higher in patients with KAF than in patients with NAF.<sup>18</sup> A hospital-based cohort showed that the in-hospital mortality rate was approximately 15% in the KAF and NAF groups of patients.<sup>19</sup> An inception cohort showed a 12.2% per year mortality rate in KAF and a 15.8% per year mortality rate in AF diagnosed within 6 months after index stroke.<sup>7</sup> The discrepancies in the studied populations and clinical evaluations made the comparisons among studies difficult. In the present study, the risks of recurrent IS and hemorrhagic stroke were higher in the patients with NAF than in the patients with KAF and patients without AF. The differences in risk factors and comorbidities between KAF and NAF were unlikely to contribute to the increases in recurrent IS and hemorrhagic stroke in NAF because the patients with KAF had higher CHA<sub>2</sub>DS<sub>2</sub>-VASc scores and more cardiovascular comorbidities than those of the patients with NAF. Compared with the NAF group, the KAF group had a 1.5% absolute lower incidence of recurrent IS and an 11.0% absolute higher incidence of all-cause mortality. The high mortality rate in the patients with KAF could be a competing risk for recurrent IS and hemorrhagic stroke.

The high mortality rates in the patients with KAF and patients with NAF in our real-world cohort are noteworthy. Previous cohorts of Chinese patients with IS and AF reportedly had 1-year mortality rates ranging from 15.7% to 22.1%.<sup>6,18</sup> Longer follow-up periods and older age might have contributed to the high mortality rates in our cohort. The relatively high incidence of heart failure in our patients with KAF



may also have contributed to the high mortality rate. In a meta-analysis of 71,683 patients from four randomized trials of DOACs, the adjusted mortality rate was 4.72% per year.<sup>20</sup> Pooled data from prospective cohorts showed a 10.2% per year mortality rate during 6,128 patient-years of follow-up in 5,314 patients.<sup>21</sup> The mortality rates were higher in real-world cohorts than the rates in randomized trials. Compared with patients with NAF, patients without stroke but with newly diagnosed nonvalvular AF had an all-cause mortality rate of 3.83 per 100 person-years in the global observational GARFIELD-AF study.<sup>22</sup> The patients with AF and IS seemed more vulnerable than all patients with AF. There is a strong need to refine treatment modalities to improve post-stroke care and reduce stroke-related mortality. However, a previous study suggested that the majority of deaths in patients with AF were attributable to cardiovascular etiologies.<sup>17,20,23</sup> Rhythm control with either AF ablation or antiarrhythmic drug therapy might decrease cardiovascular deaths in patients with either KAF or NAF.<sup>24,25</sup> Further studies to investigate the long-term outcomes and causes of death in patients with stroke and AF are necessary to design effective interventions to reduce the high mortality in the population.

The incidences of NAF (4.9%) and KAF (10.5%) in our cohort were similar to those in previous stroke registries.<sup>6,26</sup> An early study that used the similar patient screening criteria and Taiwan NHIRD found only 481 patients with KAF and 680 patients with NAF between 2000 and 2012.<sup>18</sup> Improved awareness of AF could contribute to the marked increase in AF diagnosis in patients with IS in the mid-2010s in Taiwan. Previous studies have found that the incidence of post-stroke AF varied from 3.2% to 24%.<sup>27</sup> Patients with acute IS reportedly have in-hospital NAF rates between 11.5% and 12.8% in countries in the West.<sup>19,28,29</sup> Because IS is more frequently caused by small-vessel diseases and intracranial arterial stenosis in the Chinese population,<sup>26,30</sup> ethnic differences might have contributed to the low incidences of NAF and KAF in our cohort. A meta-analysis showed that NAF was detected in 5.1% of patients with IS during monitoring of <72 hours, whereas the rate of NAF increased to 15% with monitoring of >7 days.<sup>31</sup> The percentage of NAF in our cohort was relatively low, probably because of ethnic differences and infrequent use of long-term cardiac monitoring in real-world practice. However, the vast majority of NAF diagnoses could be made by 12-lead EKG or standard rhythm monitoring (telemetry and/or rhythm strips).<sup>19</sup> Prolongation of cardiac monitoring might serve to detect less clinically relevant AF in low-risk populations.<sup>32</sup> Current guidelines suggest the use of long-term cardiac monitoring in selected patients only.<sup>4,33</sup>

In the present study, the patients with NAF included those who had preexisting AF



but undiagnosed before the index stroke and those who had newly developed AF after a stroke, so-called neurogenic AF. Strictly speaking, neurogenic AF is AF diagnosed through long-term cardiac monitoring in patients with a cryptogenic stroke after initial evaluation.<sup>34</sup> Neurogenic AF, which is caused by hyperactivity and an imbalanced central nervous system, systemic inflammation, and endothelial dysfunction caused by stroke,<sup>34,35</sup> has been hypothesized to be a relatively benign low-burden AF. The NAF rate was higher in our cohort than in cohorts in other studies that used a restricted definition for newly developed AF after a stroke.<sup>5</sup> Compared with the non-AF group, the NAF group in our cohort had higher stroke severity, older age, and higher incidences of coronary artery disease and heart failure. The differences in clinical characteristics and outcomes between the NAF and non-AF groups suggested that the majority of our patients with NAF might have cardiac myopathy and preexisting AF before the index stroke rather than neurogenic AF. The high incidence of recurrent IS and hemorrhagic stroke in NAF patients indicated that NAF was not a benign condition. Raising awareness of AF in communities and implementing standardized evaluations in high-risk patients to detect AF before stroke occurrence are essential for adequate interventions to decrease the AF-related morbidity and future devastating events.<sup>25,36</sup>

Anticoagulants were used in 51.6% of the KAF patients and 62.7% of the NAF patients in our cohort, and the prescription rates of anticoagulants were higher than those in previous studies.<sup>6,18</sup> The rates of recurrent strokes were high in our study because of longer follow-up periods and higher CHA<sub>2</sub>DS<sub>2</sub>-VASc scores.

Anticoagulant use significantly reduced the risks of recurrent IS and mortality as well as protected patients from hemorrhagic stroke. Our study provided robust real-world evidence of the benefits of anticoagulants use, mostly DOACs, in patients with IS and AF. Although the AF patients with higher risk of bleeding complications probably were not taking anticoagulants in our cohort, which would create selection bias, anticoagulants use in more than a half of our patients with AF was beneficial without an increased risk of hemorrhagic stroke in this large real-world cohort. Our results supported the importance of diagnosis and anticoagulant treatment of AF in patients with IS. High bleeding risks should not be a reason to withhold anticoagulants.<sup>10</sup>

This study had several limitations. The topography of brain infarcts and the mechanisms of strokes could not be specified because we were unable to review electrocardiography and neuroimaging findings. Misclassification bias may occur; for example, AF patients might have lacunar infarction or ischemic stroke due to severe stenosis in a corresponding large artery or hypotension. The adherence to

anticoagulants was assessed indirectly through dispensed prescriptions. The reasons for withholding anticoagulants in patients with AF were unknown. Those who did not take anticoagulants might have had an inherently increased baseline risk of stroke or be more vulnerable to bleeding complications. Hemorrhagic complications other than intracerebral hemorrhage were not evaluated. The workups for detecting AF were not standardized. Paroxysmal AF might be undiagnosed due to nonroutine use of long-term cardiac monitoring modalities. AF could be under-reported because the diagnosis of AF was based on claims data. Consequently, the possibility of incomplete clinical coding in some patients could not be excluded. The CHA<sub>2</sub>DS<sub>2</sub>-VASc and SSI scores, which were calculated retrospectively, could have been underestimated. Validated equations were used to derive the severity of stroke from claims data rather than directly from the primary record. Therefore, the generalizability of our results to different ethnic populations is unknown and requires additional studies.

In conclusion, the incidences of comorbidities were higher, stroke was more severe, and the risks of recurrent strokes and all-cause mortality were higher in the patients with KAF or NAF than in the patients without AF. Anticoagulant treatment was found to reduce the risks of recurrent IS, hemorrhagic stroke, and all-cause mortality. The risks of recurrent IS and hemorrhagic stroke were higher but the risk of all-cause mortality was lower in the patients with NAF than in the patients with KAF.

## **Affiliations**

Department of Medical Research, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan (Y.K.C.). Department of Life Science, College of Life Science, National Chung Hsing University, Taichung, Taiwan (Y.K.C., H.Y.H.). Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan (Y.K.C.). Department of Nursing, Jenteh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan (Y.K.C.). Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan (C.C.H., C.T.H.). National Center for Geriatrics and Welfare Research, National Health Research Institutes, Yunlin, Taiwan (C.C.H.). Department of Neurology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan (C.H.L., H.Y.H.).

## **Sources of Funding**

This work was funded by grants from Tungs' Taichung Metroharbor Hospital (protocol number TTMHH-109R0005).

## **Disclosures**

**All authors have** no conflicts of interest to declare.

## **Ethical approval**

The study was approved by the ethical committee of Tungs' Taichung MetroHarbor Hospital in Taichung, Taiwan (protocol number 108077) and written informed consent was received from all patients.

## REFERENCES

1. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. *Lancet*. 2016;388:806-817. doi: 10.1016/S0140-6736(16)31257-0
2. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA*. 2003;290:1049-1056. doi: 10.1001/jama.290.8.1049
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137:263-272. doi: 10.1378/chest.09-1584
4. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42:373-498. doi: 10.1093/eurheartj/ehaa612
5. Sposato LA, Cerasuolo JO, Cipriano LE, Fang J, Fridman S, Paquet M, Saposnik G, Group PS. Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence. *Neurology*. 2018;90:e924-e931. doi: 10.1212/WNL.0000000000005126
6. Yang XM, Rao ZZ, Gu HQ, Zhao XQ, Wang CJ, Liu LP, Liu C, Wang YL, Li ZX, Xiao RP, Wang YJ. Atrial Fibrillation Known Before or Detected After Stroke Share Similar Risk of Ischemic Stroke Recurrence and Death. *Stroke*. 2019;50:1124-1129. doi: 10.1161/STROKEAHA.118.024176
7. Bhatla A, Borovskiy Y, Katz R, Hyman MC, Patel PJ, Arkles J, Callans DJ, Chokshi N, Dixit S, Epstein AE, et al. Stroke, Timing of Atrial Fibrillation Diagnosis, and Risk of Death. *Neurology*. 2021;96:e1655-e1662. doi: 10.1212/WNL.0000000000011633
8. Lip GY, Hunter TD, Quiroz ME, Ziegler PD, Turakhia MP. Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke. *Circ Cardiovasc Qual Outcomes*. 2017;10. doi: 10.1161/CIRCOUTCOMES.116.002864
9. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Jr., Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS

- Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation*. 2019;140:e125-e151. doi: 10.1161/CIR.0000000000000665
10. Chiang CE, Chao TF, Choi EK, Lim TW, Krittayaphong R, Li M, Chen M, Guo Y, Okumura K, Lip GYH. Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 2). *JACC Asia*. 2022;2:519-537. doi: 10.1016/j.jacasi.2022.06.004
  11. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. *J Formos Med Assoc*. 2005;104:157-163.
  12. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoepidemiol Drug Saf*. 2011;20:236-242. doi: 10.1002/pds.2087
  13. Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. *Stroke*. 2004;35:1941-1945. doi: 10.1161/01.STR.0000135225.80898.1c
  14. Hung LC, Sung SF, Hsieh CY, Hu YH, Lin HJ, Chen YW, Yang YK, Lin SJ. Validation of a novel claims-based stroke severity index in patients with intracerebral hemorrhage. *J Epidemiol*. 2017;27:24-29. doi: 10.1016/j.je.2016.08.003
  15. Sung SF, Hsieh CY, Lin HJ, Chen YW, Chen CH, Kao Yang YH, Hu YH. Validity of a stroke severity index for administrative claims data research: a retrospective cohort study. *BMC Health Serv Res*. 2016;16:509. doi: 10.1186/s12913-016-1769-8
  16. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA*. 2001;285:2864-2870. doi: 10.1001/jama.285.22.2864
  17. Kaarisalo MM, Immonen-Raiha P, Marttila RJ, Salomaa V, Kaarsalo E, Salmi K, Sarti C, Sivenius J, Torppa J, Tuomilehto J. Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. *Stroke*. 1997;28:311-315. doi: 10.1161/01.str.28.2.311
  18. Hsieh CY, Lee CH, Wu DP, Sung SF. Characteristics and outcomes of ischemic stroke in patients with known atrial fibrillation or atrial fibrillation diagnosed after stroke. *Int J Cardiol*. 2018;261:68-72. doi:

- 10.1016/j.ijcard.2017.11.047
19. Borowsky LH, Regan S, Chang Y, Ayres A, Greenberg SM, Singer DE. First Diagnosis of Atrial Fibrillation at the Time of Stroke. *Cerebrovasc Dis*. 2017;43:192-199. doi: 10.1159/000457809
  20. Gomez-Outes A, Lagunar-Ruiz J, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. *J Am Coll Cardiol*. 2016;68:2508-2521. doi: 10.1016/j.jacc.2016.09.944
  21. Seiffge DJ, De Marchis GM, Koga M, Paciaroni M, Wilson D, Cappellari M, Macha Md K, Tsivgoulis G, Ambler G, Arihiro S, et al. Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. *Ann Neurol*. 2020;87:677-687. doi: 10.1002/ana.25700
  22. Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. *Eur Heart J*. 2016;37:2882-2889. doi: 10.1093/eurheartj/ehw233
  23. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, Ivanes F, Babuty D, Lip GY. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. *Am J Med*. 2016;129:1278-1287. doi: 10.1016/j.amjmed.2016.06.045
  24. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. *N Engl J Med*. 2020;383:1305-1316. doi: 10.1056/NEJMoa2019422
  25. Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, Camm AJ, Casadei B, Chua W, Dagues N, et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. *Europace*. 2023;25:6-27. doi: 10.1093/europace/euac062
  26. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, Chen YW, Chen CH, Jeng JS, Tsai SY, et al. Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. *Circulation*. 2010;122:1116-1123. doi: 10.1161/CIRCULATIONAHA.110.936526
  27. Wang Y, Qian Y, Smerin D, Zhang S, Zhao Q, Xiong X. Newly Detected Atrial Fibrillation after Acute Stroke: A Narrative Review of Causes and Implications. *Cardiology*. 2019;144:112-121. doi: 10.1159/000502971
  28. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski

- V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol.* 2015;14:377-387. doi: 10.1016/S1474-4422(15)70027-X
29. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: the Framingham study. *Stroke.* 1983;14:664-667. doi: 10.1161/01.str.14.5.664
30. Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. *Neurology.* 2013;81:264-272. doi: 10.1212/WNL.0b013e31829bfde3
31. Dussault C, Toeg H, Nathan M, Wang ZJ, Roux JF, Secemsky E. Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. *Circ Arrhythm Electrophysiol.* 2015;8:263-269. doi: 10.1161/CIRCEP.114.002521
32. Tsivgoulis G, Triantafyllou S, Palaiodimou L, Grory BM, Deftereos S, Kohrmann M, Dilaveris P, Ricci B, Tsioufis K, Cutting S, et al. Prolonged Cardiac Monitoring and Stroke Recurrence: A Meta-analysis. *Neurology.* 2022;98:e1942-e1952. doi: 10.1212/WNL.0000000000200227
33. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockcroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke.* 2021;52:e364-e467. doi: 10.1161/STR.0000000000000375
34. Sposato LA, Chaturvedi S, Hsieh CY, Morillo CA, Kamel H. Atrial Fibrillation Detected After Stroke and Transient Ischemic Attack: A Novel Clinical Concept Challenging Current Views. *Stroke.* 2022;53:e94-e103. doi: 10.1161/STROKEAHA.121.034777
35. Fridman S, Jimenez-Ruiz A, Vargas-Gonzalez JC, Sposato LA. Differences between Atrial Fibrillation Detected before and after Stroke and TIA: A Systematic Review and Meta-Analysis. *Cerebrovasc Dis.* 2022;51:152-157. doi: 10.1159/000520101
36. Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, Brandes A, Bustamante A, Casadei B, Crijns H, et al. Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. *Circulation.* 2019;140:1834-1850. doi: 10.1161/CIRCULATIONAHA.119.040267



**Table 1. Clinical characteristics, antithrombotic medications and outcomes of study populations**

|                                       | KAF, n(%)    | NAF, n(%)    | Non-AF, n(%)    | <i>p</i> value |
|---------------------------------------|--------------|--------------|-----------------|----------------|
|                                       | (n=16699)    | (n=7826)     | (n=134384)      |                |
| Sex (male)                            | 8414 (50.4)  | 4148 (53.0)* | 81418 (60.6)*#  | <.0001         |
| Age (year), mean (SD)                 | 77.8 (10.8)  | 76.1 (11.6)* | 69.3 (13.9)*#   | <.0001         |
| Age (year)                            |              |              |                 | <.0001         |
| <65                                   | 2207 (13.2)  | 1421 (18.2)  | 50185 (37.3)    |                |
| 65-74                                 | 3554 (21.3)  | 1807 (23.1)  | 32833 (24.4)    |                |
| 75 <sup>+</sup>                       | 10938 (65.5) | 4598 (58.8)  | 51366 (38.2)    |                |
| Risk factors                          |              |              |                 |                |
| Hypertension                          | 11336 (67.9) | 4607 (58.9)* | 74913 (55.8)*#  | <.0001         |
| Diabetes mellitus                     | 5346 (32.0)  | 1903 (24.3)* | 43706 (32.5)#   | <.0001         |
| Hyperlipidemia                        | 3481 (20.9)  | 1643 (21.0)  | 31408 (23.4)*#  | <.0001         |
| Coronary artery disease               | 2750 (16.5)  | 582 (7.4)*   | 8826 (6.6)*!    | <.0001         |
| Heart failure                         | 4907 (29.4)  | 620 (7.9)*   | 6529 (4.9)*#    | <.0001         |
| Peripheral artery disease             | 768 (4.6)    | 210 (2.7)*   | 3493 (2.6)*     | <.0001         |
| Chronic kidney disease                | 2088 (12.5)  | 501 (6.4)*   | 10129 (7.5)*#   | <.0001         |
| Chronic obstructive pulmonary disease | 1719 (10.3)  | 352 (4.5)*   | 6387 (4.8)*     | <.0001         |
| Prior stroke                          | 1261 (7.6)   | 347 (4.4)*   | 8894 (6.6)*#    | <.0001         |
| Modified CCI score, mean (SD)         | 1.2 (1.6)    | 0.6 (1.2)*   | 0.9 (1.5)*#     | <.0001         |
| SSI, mean (SD)                        | 11.6 (6.4)   | 11.4 (6.4)   | 8.2 (5.5)*#     | <.0001         |
| NIHSS                                 |              |              |                 | <.0001         |
| <8                                    | 6113 (36.6)  | 2862 (36.6)  | 82128 (61.1) *# |                |
| 8-15                                  | 3884 (23.3)  | 1879 (24)    | 26684 (19.9) *# |                |
| >15                                   | 6702 (40.1)  | 3085 (39.4)  | 25572 (19.0) *# |                |

|   |             |                  |                 |        |
|---|-------------|------------------|-----------------|--------|
|   |             |                  |                 |        |
| CHA <sub>2</sub> DS <sub>2</sub> -VASc, mean (SD) | 4.9 (1.8)   | 3.8 (1.9)*       | 3.4 (2.0)*#     | <.0001 |
| CHA <sub>2</sub> DS <sub>2</sub> , mean (SD)      | 3 (1.4)     | 2.1 (1.3)*       | 2.1 (1.5)*#     | <.0001 |
| Antithrombotic treatment                          |             |                  |                 |        |
| Antiplatelet                                      | 9295 (55.7) | 4417 (56.4)      | 104451 (77.7)*# | <.0001 |
| Warfarin  | 2505 (15.0) | 1085 (13.9)§     | 3576 (2.7)*#    | <.0001 |
| DOAC  | 6114 (36.6) | 3821 (48.8)*     | 3183 (2.4)*#    | <.0001 |
| Outcomes  |             |                  |                 |        |
| Recurrent ischemic stroke                         | 3503 (21.0) | 1763 (22.5)<br>@ | 24341 (18.1) *# | <.0001 |
| Intracranial hemorrhage                           | 890 (5.3)   | 503 (6.4) *      | 6517 (4.9) @#   | <.0001 |
| All-cause mortality                               | 9282 (55.6) | 3492 (44.6) *    | 41564 (30.9) *# | <.0001 |

KAF: known atrial fibrillation; NAF: newly diagnosed atrial fibrillation diagnosed after stroke; Non-AF: without atrial fibrillation; SD: standard deviation; CCI: Charlson comorbidity index; SSI: stroke severity index; NIHSS: national institutes of health stroke scale; DOACs: direct-acting oral anticoagulants.

\*p<0.001 vs. KAF; @p <0.01 vs. KAF; # p<0.001 vs. NAF; § p <0.05 vs. KAF; ! P<0.01 vs NAF

**Table 2. Univariable and multivariable Cox regression models to predict the recurrent ischemic stroke at the end of follow-up**

|  | Univariable        |                | Multivariable      |                |
|--|--------------------|----------------|--------------------|----------------|
|  | HR(95%CI)          | <i>p</i> value | HR(95%CI)          | <i>p</i> value |
| Sex (male vs. female)                  | 1.13(1.10-1.15)    | <.0001         | 1.16(1.13-1.19)    | <.0001         |
| Age                                    |                    |                |                    |                |
| <65                                    | Ref.               | Ref.           | Ref.               | Ref.           |
| 65-74                                  | 1.09(1.06-1.13)    | <.0001         | 1.07(1.04-1.10)    | <.0001         |
| 75 <sup>+</sup>                        | 1.09(1.06-1.12)    | <.0001         | 1.02(0.99-1.05)    | 0.1506         |
| Risk factors                           |                    |                |                    |                |
| Hypertension (Yes vs. No)              | 1.09(1.06-1.11)    | <.0001         | 1.04(1.02-1.07)    | 0.0010         |
| Diabetes mellitus (Yes vs. No)         | 1.12(1.09-1.15)    | <.0001         | 1.09(1.06-1.12)    | <.0001         |
| Hyperlipidemia (Yes vs. No)            | 1.05(1.02-1.08)    | 0.0006         | 1.02(0.99-1.05)    | 0.2792         |
| Coronary artery disease (Yes vs. No)   | 1.16(1.11-1.21)    | <.0001         | 1.07(1.02-1.11)    | 0.0034         |
| Heart failure (Yes vs. No)             | 1.15(1.10-1.20)    | <.0001         | 1.06(1.01-1.11)    | 0.0131         |
| Peripheral artery disease (Yes vs. No) | 1.19(1.11-1.27)    | <.0001         | 1.12(1.05-1.19)    | 0.0011         |
| Chronic kidney disease (Yes vs. No)    | 1.02(0.97-1.07)    | 0.3999         | 0.92(0.88-0.97)    | 0.0007         |
| Prior stroke/TIA (Yes vs. No)          | 1.09(1.05-1.14)    | <.0001         | 1.06(1.01-1.11)    | 0.0091         |
| Modified CCI score                     | 1.03(1.02-1.04)    | <.0001         | 1.00(0.99-1.01)    | 0.5628         |
| SSI                                    | 1.071(1.068-1.073) | <.0001         | 1.070(1.068-1.072) | <.0001         |
| Anticoagulant treatment (Yes vs. No)   | 0.56(0.54-0.59)    | <.0001         | 0.35(0.33-0.36)    | <.0001         |
| AF subtype                             |                    |                |                    |                |
| Non-AF                                 | Ref.               | Ref.           | Ref.               | Ref.           |
| NAF                                    | 1.33(1.29-1.38)    | <.0001         | 2.37(2.25-2.50)    | <.0001         |
| KAF                                    | 1.34(1.27-1.41)    | <.0001         | 2.03(1.95-2.11)    | <.0001         |

KAF: known atrial fibrillation; NAF: newly diagnosed atrial fibrillation diagnosed after stroke; Non-AF: without atrial fibrillation; TIA: transient ischemic attack; CCI: Charlson comorbidity index; SSI: stroke severity index.  
Ref.: reference

**Table 3. Univariable and multivariable Cox regression models to predict the hemorrhage stroke at the end of follow-up**

|  | Univariable        |                | Multivariable      |                |
|--|--------------------|----------------|--------------------|----------------|
|  | HR(95%CI)          | <i>p</i> value | HR(95%CI)          | <i>p</i> value |
| Sex (male vs. female)                  | 1.19(1.13-1.25)    | <.0001         | 1.17(1.12-1.23)    | <.0001         |
| Age                                    |                    |                |                    |                |
| <65                                    | Ref.               | Ref.           | Ref.               | Ref.           |
| 65-74                                  | 0.94(0.87-0.99)    | 0.0365         | 0.95(0.90-1.01)    | 0.0756         |
| 75 <sup>+</sup>                        | 0.89(0.84-0.93)    | <.0001         | 0.87(0.83-0.92)    | <.0001         |
| Risk factors                           |                    |                |                    |                |
| Hypertension (Yes vs. No)              | 0.92(0.88-0.97)    | 0.0007         | 0.98(0.94-1.03)    | 0.4738         |
| Diabetes mellitus (Yes vs. No)         | 0.95(0.90-0.99)    | 0.0378         | 1.00(0.95-1.06)    | 0.9709         |
| Hyperlipidemia (Yes vs. No)            | 0.92(0.87-0.97)    | 0.0015         | 0.97(0.91-1.02)    | 0.2334         |
| Coronary artery disease (Yes vs. No)   | 0.89(0.82-0.98)    | 0.0185         | 0.89(0.81-0.97)    | 0.0121         |
| Heart failure (Yes vs. No)             | 0.99(0.90-1.09)    | 0.8578         | 0.99(0.90-1.09)    | 0.8492         |
| Peripheral artery disease (Yes vs. No) | 0.91(0.78-1.05)    | 0.1961         | 0.95(0.82-1.10)    | 0.4753         |
| Chronic kidney disease (Yes vs. No)    | 0.99(0.91-1.09)    | 0.8776         | 1.03(0.94-1.13)    | 0.5483         |
| Prior stroke/TIA (Yes vs. No)          | 0.92(0.85-1.00)    | 0.0623         | 0.79(0.72-0.87)    | <.0001         |
| Modified CCI score                     | 0.98(0.97-0.99)    | 0.0017         | 0.99(0.97-1.01)    | 0.3651         |
| SSI                                    | 1.069(1.065-1.073) | <.0001         | 1.073(1.069-1.077) | <.0001         |
| Anticoagulant treatment (Yes vs. No)   | 0.66(0.61-0.71)    | <.0001         | 0.42(0.38-0.45)    | <.0001         |
| AF subtype                             |                    |                |                    |                |
| Non-AF                                 | Ref.               | Ref.           | Ref.               | Ref.           |
| NAF                                    | 1.26(1.17-1.35)    | <.0001         | 2.43(2.20-2.69)    | <.0001         |
| KAF                                    | 1.43(1.30-1.57)    | <.0001         | 2.06(1.90-2.24)    | <.0001         |

KAF: known atrial fibrillation; NAF: newly diagnosed atrial fibrillation diagnosed after stroke; Non-AF: without atrial fibrillation; TIA: transient ischemic attack; CCI: Charlson comorbidity index; SSI: stroke severity index.  
Ref.: reference

**Table 4. Univariable and multivariable Cox regression models to predict the all cause mortality at the end of follow-up**

|  | Univariable        |                | Multivariable      |                |
|--|--------------------|----------------|--------------------|----------------|
|  | HR(95%CI)          | <i>p</i> value | HR(95%CI)          | <i>p</i> value |
| Sex (male vs. female)                  | 0.83(0.81-0.85)    | <.0001         | 1.06(1.05-1.08)    | <.0001         |
| Age                                    |                    |                |                    |                |
| <65                                    | Ref.               | Ref.           | Ref.               | Ref.           |
| 65-74                                  | 1.60(1.54-1.66)    | <.0001         | 1.59(1.54-1.63)    | <.0001         |
| 75 <sup>+</sup>                        | 3.81(3.70-3.92)    | <.0001         | 3.45(3.36-3.53)    | <.0001         |
| Risk factors                           |                    |                |                    |                |
| Hypertension (Yes vs. No)              | 1.32(1.29-1.35)    | <.0001         | 0.93(0.91-0.95)    | <.0001         |
| Diabetes mellitus (Yes vs. No)         | 1.29(1.27-1.32)    | <.0001         | 1.02(1.00-1.05)    | 0.0236         |
| Hyperlipidemia (Yes vs. No)            | 0.79(0.77-0.81)    | <.0001         | 0.74(0.74-0.78)    | <.0001         |
| Coronary artery disease (Yes vs. No)   | 1.58(1.53-1.64)    | <.0001         | 1.01(0.98-1.04)    | 0.4948         |
| Heart failure (Yes vs. No)             | 2.63(2.55-2.71)    | <.0001         | 1.44(1.41-1.48)    | <.0001         |
| Peripheral artery disease (Yes vs. No) | 1.69(1.60-1.78)    | <.0001         | 1.09(1.04-1.13)    | 0.0002         |
| Chronic kidney disease (Yes vs. No)    | 2.34(2.27-2.41)    | <.0001         | 1.36(1.33-1.40)    | <.0001         |
| Prior stroke/TIA (Yes vs. No)          | 1.33(1.28-1.37)    | <.0001         | 0.90(0.87-0.92)    | <.0001         |
| Modified CCI score)                    | 1.208(1.202-1.213) | <.0001         | 1.19(1.18-1.19)    | <.0001         |
| SSI                                    | 1.182(1.180-1.184) | <.0001         | 1.169(1.167-1.171) | <.0001         |
| Anticoagulant treatment (Yes vs. No)   | 0.74(0.72-0.77)    | <.0001         | 0.51(0.49-0.52)    | <.0001         |
| AF subtype                             |                    |                |                    |                |
| Non-AF                                 | Ref.               | Ref.           | Ref.               | Ref.           |
| NAF                                    | 2.29(2.23-2.35)    | <.0001         | 1.97(1.90-2.05)    | <.0001         |
| KAF                                    | 1.61(1.54-1.68)    | <.0001         | 1.93(1.88-1.99)    | <.0001         |

KAF: known atrial fibrillation; NAF : newly diagnosed atrial fibrillation diagnosed after stroke; Non-AF: without atrial fibrillation; TIA: transient ischemic attack; CCI: Charlson comorbidity index; SSI: stroke severity index.

Ref.: reference

**Table 5. Multivariable Cox regression models to predict the outcome of recurrent ischemic stroke, hemorrhage stroke, or death at the end of follow-up**

| Outcome Measures                 | Non-AF            | NAF               | KAF               |
|----------------------------------|-------------------|-------------------|-------------------|
| <b>Recurrent ischemic stroke</b> |                   |                   |                   |
| n(%)                             | 24341(18.1)       | 1763(22.5)        | 3503(21.0)        |
| HR (95%CI)#                      | Ref.              | 1.81(1.71-1.90)** | 1.65(1.59-1.72)** |
| HR (95%CI)#                      | 0.55(0.53-0.58)** | Ref.              | 0.91(0.86-0.97)*  |
| <b>Hemorrhage stroke</b>         |                   |                   |                   |
| n(%)                             | 6517(4.8)         | 503(6.4)          | 890(5.3)          |
| HR (95%CI)#                      | Ref.              | 1.88(1.70-2.08)** | 1.66(1.53-1.80)** |
| HR (95%CI)#                      | 0.53(0.48-0.59)** | Ref.              | 0.88(0.79-0.99)*  |
| <b>Death</b>                     |                   |                   |                   |
| n(%)                             | 41564(30.9)       | 3492(44.6)        | 9282(55.6)        |
| HR (95%CI)#                      | Ref.              | 1.27(1.22-1.31)** | 1.41(1.37-1.45)** |
| HR (95%CI)#                      | 0.79(0.76-0.82)** | Ref.              | 1.11(1.07-1.16)** |

KAF: known atrial fibrillation; NAF: newly diagnosed atrial fibrillation diagnosed after stroke; Non-AF: without atrial fibrillation; CI: confidence interval.

Ref.: reference.

#Adjusted sex, age, SSI, risk factors, modified CCI score.

\*P<0.01; \*\*P<0.001.